Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Hydroxyguanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 3/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyguanidine SCHEMBL8874240 | 0.97 | BLM (0.46) | BLMKDM4ECYP2D6CYP2C19NPSR1 | |
| Hydroxyguanidine SCHEMBL116224 | 0.82 | — | — | |
| Pimagedine SCHEMBL728583 | 0.80 | KDM4E (0.48) | BLMKDM4ECYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL19458399 | 0.80 | KDM4E (0.48) | BLMKDM4ECYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL30481084 | 0.80 | KDM4E (0.48) | BLMKDM4ECYP2D6CYP2C19NPSR1 | |
| Pimagedine SCHEMBL439903 | 0.80 | KDM4E (0.48) | BLMKDM4ECYP2D6CYP2C19NPSR1 | |
| Biguanide SCHEMBL2670547 | 0.80 | KDM4E (0.48) | BLMKDM4ECYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL1318239 | 0.78 | BLM (0.59) | BLMKDM4ECYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL170524 | 0.78 | — | — | |
| Hydroxyguanidine SCHEMBL11834471 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | claimed |
| EP-4426274-A1 | NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY | Baxter International Inc. (US) | 2024-09-11 | — | — | EP | claimed |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | KEEFER, Edward (US) | 2024-08-29 | — | — | US | claimed |
| US-11969522-B2 | Use of immune modulators to improve nerve regeneration | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-30 | — | — | US | claimed |
| WO-2023081681-A1 | NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY | BAXTER INTERNATIONAL INC. (US) | 2023-05-11 | — | — | WO | claimed |
| US-20230140515-A1 | NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY | BAXTER INTERNATIONAL INC. | 2023-05-04 | — | — | US | claimed |
| CN-113698322-B | Continuous production process method of hydroxyguanidine sulfate | 大连理工大学 | 2022-11-04 | — | — | CN | claimed |
| CN-113698322-A | Continuous production process method of hydroxyguanidine sulfate | 大连理工大学 | 2021-11-26 | — | — | CN | claimed |
| CN-103751943-A | Fire extinguishing composition containing nitrogenous organic compound | XI AN JIAN RUI SAFETY EMERGENCY EQUIPMENT LTD LIABILITY COMPANY | 2014-04-30 | — | — | CN | claimed |
| US-20090203050-A1 | MOLECULAR SIGNALING PATHWAYS TRIGGERED BY RITUXIMAB: PROGNOSTIC, DIAGNOSTIC, AND THERAPEUTIC USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-13 | — | — | US | claimed |
| US-20080311039-A1 | Therapeutic and Prognostic Factor Yy1 in Human Cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-12-18 | — | — | US | claimed |
| US-20070172847-A1 | MOLECULAR SIGNALING PATHWAYS TRIGGERED BY RITUXIMAB: PROGNOSTIC, DIAGNOSTIC, AND THERAPEUTIC USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-07-26 | — | — | US | claimed |
| WO-2007011372-A2 | THERAPEUTIC AND PROGNOSTIC FACTOR YY1 IN HUMAN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-25 | — | — | WO | claimed |
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | disclosed |
| US-20250186537-A1 | TREATMENT OF WOMEN AFFECTED WITH POLYCYSTIC OVARY SYNDROME | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2025-06-12 | — | — | US | disclosed |
| US-12208130-B2 | Treatment of women affected with polycystic ovary syndrome | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2025-01-28 | — | — | US | disclosed |
| EP-0118543-A1 | SUBSTITUTED N-BENZENESULFONYLOXYPHTHALIMIDES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1984-09-19 | — | — | EP | disclosed |
| US-4446142-A | HYPOTENSIVE AGENTS | BEIERSDORF AKTIENGESELLSCHAFT (DE) | 1984-05-01 | — | — | US | disclosed |
| WO-1984000888-A1 | SUBSTITUTED N-BENZENESULFONYLOXYPHTHALIMIDES | UNIV SOUTHERN CALIFORNIA (US) | 1984-03-15 | — | — | WO | disclosed |
| EP-0044266-A2 | Substituted 3,5-diamino-1,2,4-oxadiazoles and 3,5-diamino-1,2,4-thiadiazoles, their preparation and pharmaceutical compositions containing them | Beiersdorf Aktiengesellschaft (DE) | 1982-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | CXCR3, CXCL12, CXCR4 | BLM 2727/4885KDM4E 3304/4885CYP2D6 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.